Literature DB >> 9708617

Reduction in arteriovenous graft impairment: results of a vascular access surveillance protocol.

A V Cayco1, A K Abu-Alfa, R L Mahnensmith, M A Perazella.   

Abstract

Impairment of hemodialysis (HD) vascular access, remains a frustrating problem for both the patient who possesses an arteriovenous graft (AVG) and the nephrologist who cares for the patient. We instituted a vascular access surveillance protocol intended to detect and correct evolving stenosis in patients with AVGs. The principal screen was the observation of dynamic venous pressure (VP) at a blood flow rate of 200 mL/min during the first 5 minutes of each HD session. If VP at a blood flow rate of 200 mL/min was 140 mm Hg or greater in three of six consecutive readings, recirculation greater than 15% on two observations, graft-arm swelling observed, or prolonged bleeding postdialysis observed, then the patient was referred for angiography and then angioplasty or surgery if a vascular stenosis of greater than 50% was documented. Sixty-four patients with a synthetic AVG comprised the study group. Seventy-two episodes of AVG impairment (56 with stenosis > or = 50% on angiography, 16 with thrombosis) occurred in these patients during the study period. In 63 of 72 impairment episodes, the preceding vascular access screening test was positive. The calculated sensitivity and specificity of the vascular access protocol was 88% and 81%, respectively. Calculation of the sensitivity and specificity for the VP alone was 81% and 85%, respectively. Comparison of the study group with a similar historical control group (55 patients) showed a significantly lower thrombosis rate (P = 0.03; 95% confidence interval [CI], 0.025 to 0.375) in the study group (0.29 thrombotic episodes/graft-year at risk) versus the historical control group (0.49 thrombotic episodes/graft-year at risk). In summary, a vascular access surveillance protocol is a useful tool to predict patients at risk for AVG venous stenosis and/or thrombosis. A dynamic VP of 140 mm Hg or greater appears to be the optimal threshold pressure. A decrease in synthetic AVG thrombosis rate resulted from the use of this surveillance protocol.

Entities:  

Mesh:

Year:  1998        PMID: 9708617     DOI: 10.1053/ajkd.1998.v32.pm9708617

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

Review 1.  Preserving function and long-term patency of dialysis access.

Authors:  J A Akoh; N S Hakim
Journal:  Ann R Coll Surg Engl       Date:  1999-09       Impact factor: 1.891

2.  How is arteriovenous fistula longevity best prolonged?: The role of surveillance.

Authors:  Loay H Salman
Journal:  Semin Dial       Date:  2014-09-18       Impact factor: 3.455

3.  A Patient with Recurrent Arteriovenous Graft Thrombosis.

Authors:  Michael Allon
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-16       Impact factor: 8.237

4.  Surveillance of hemodialysis vascular access.

Authors:  William L Whittier
Journal:  Semin Intervent Radiol       Date:  2009-06       Impact factor: 1.513

Review 5.  Hemodialysis vascular access monitoring: current concepts.

Authors:  Michael Allon; Michelle L Robbin
Journal:  Hemodial Int       Date:  2009-04       Impact factor: 1.812

6.  Effect of online haemodialysis vascular access flow evaluation and pre-emptive intervention on the frequency of access thrombosis.

Authors:  Edwin Wijnen; Frank M van der Sande; Jan H M Tordoir; Jeroen P Kooman; Karel M L Leunissen
Journal:  NDT Plus       Date:  2008-08-22

7.  A Multicenter Randomized Clinical Trial of Hemodialysis Access Blood Flow Surveillance Compared to Standard of Care: The Hemodialysis Access Surveillance Evaluation (HASE) Study.

Authors:  Loay Salman; Abid Rizvi; Gabriel Contreras; Christina Manning; Paul J Feustel; Ivy Machado; Patricia L Briones; Aamir Jamal; Nicolle Bateman; Laisel Martinez; Marwan Tabbara; Roberto I Vazquez-Padron; Arif Asif
Journal:  Kidney Int Rep       Date:  2020-08-04

8.  Arterial line pressure control enhanced extracorporeal blood flow prescription in hemodialysis patients.

Authors:  Franklin G Mora-Bravo; Alfonso Mariscal; Juan P Herrera-Felix; Salvador Magaña; Guadalupe De-La-Cruz; Nelly Flores; Laura Rosales; Martha Franco; Héctor Pérez-Grovas
Journal:  BMC Nephrol       Date:  2008-11-24       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.